Ontology highlight
ABSTRACT: Conclusion
Our findings suggest that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV treatment while awaiting LT is between 23 and 27, depending on the UNOS region. (Hepatology 2017;65:777-788).
SUBMITTER: Chhatwal J
PROVIDER: S-EPMC5319880 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Chhatwal Jagpreet J Samur Sumeyye S Kues Brian B Ayer Turgay T Roberts Mark S MS Kanwal Fasiha F Hur Chin C Donnell Drew Michael S DM Chung Raymond T RT
Hepatology (Baltimore, Md.) 20170106 3
The availability of oral direct-acting antivirals has altered the hepatitis C virus (HCV) treatment paradigm for both pre-liver transplant (LT) and post-LT patients. There is a perceived trade-off between pre-LT versus post-LT treatment of HCV-treatment may improve liver function but potentially decrease the likelihood of a necessary LT. Our objective was to identify LT-eligible patients with decompensated cirrhosis who would benefit (and not benefit) from pre-LT treatment based on their Model f ...[more]